Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GM-CSF, IFN-alpha, and IL-2 Adjuvant Therapy in High-Risk RCC
NCT01176552Phase 2Completed
- Start
- May 2004
- Primary completion
- Sep 2008
- Modality
- Cytokines & Interferons
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sargramostim, interferon alfa and aldesleukin in renal cell carcinoma (RCC). Primary endpoint: Disease-free survival at 3.5 years. Started May 2004; status: completed.
02
Drugs
sargramostiminterferon alfaaldesleukin
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT01176552.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01176552.